Akeso completes share placing, raises HK$3.49 bn for R&D

Akeso, Inc. announced the completion of its primary placing of new shares on September 4, 2025. The primary placing saw 23,550,000 shares placed at HK$149.54 per share, raising net proceeds of approximately HK$3,493.01 million for the company. This represents approximately 2.56% of the enlarged issued share capital.

The company plans to allocate approximately 80% of these net proceeds, or HK$2,794.41 million, to global and China R&D for innovative pipeline, technology platforms, infrastructure, and facilities, with expected utilization by the end of 2027. This includes clinical trials for ivonescimab and cadonilimab, other multi-regional clinical trials, non-oncology studies, and pre-clinical research.

Another 10% (HK$349.30 million) is earmarked for the commercialization of existing approved products, including Cadonilimab Injection and Ivonescimab Injection, to strengthen market positions and expand coverage. The remaining 10% (HK$349.30 million) will be used for general corporate purposes, including supplier payments, employee salaries, and administrative expenses. Additionally, a secondary placing of 3,000,000 existing shares was completed on September 1, 2025, at the same price.